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Abstract
Background: Individuals affected by severe Borderline Personality Disorder (BPD) are often heavy users of Mental
Health Services (MHS). Short-term treatments currently used in BPD therapy are useful to target disruptive
behaviors but they are less effective in reducing heavy MHS use. Therefore, alternative short-term treatments, less
complex than long-term psychodynamic psychotherapies but specifically oriented to BPD core problems, need to
be developed to reduce MHS overuse. This study aimed to evaluate the efficacy of adding Sequential Brief Adlerian
Psychodynamic Psychotherapy (SB-APP) to Supervised Team Management (STM) in BPD treatment compared to
STM alone in a naturalistic group of heavy MHS users with BPD. Effectiveness was evaluated 6 times along a two-
year follow-up.
Methods: Thirty-five outpatients who met inclusion criteria were randomly assigned to two treatment groups (STM
= 17; SB-APP = 18) and then compared. Clinical Global Impression (CGI) and CGI-modified (CGI-M) for BPD, Global
Assessment of Functioning (GAF), State-Trait Anger Expression Inventory (STAXI), and Symptom Checklist-90 Revised
(SCL-90-R) were administered at T1, T3, T6, T12, T18 and T24. At T12 the Working Alliance Inventory-Short Form
(WAI-S) was also completed. At the one-year follow-up, SB-APP group did not receive any additional individual
psychological support. MHS team was specifically trained in BPD treatment and had regular supervisions.
Results: All patients improved on CGI, GAF, and STAXI scores after 6 and 12 months, independently of treatment
received. SB-APP group showed better outcome on impulsivity, suicide attempts, chronic feelings of emptiness,
and disturbed relationships. We found a good stabilization at the one year follow-up, even after the interruption of
brief psychotherapy in the SB-APP group.
Conclusions: Although STM for BPD applied to heavy MHS users was effective in reducing symptoms and
improving their global functioning, adding a time-limited and focused psychotherapy was found to achieve a
better outcome. In particular, focusing treatment on patients’ personality with a specific psychotherapeutic
approach (i.e. SB-APP) seemed to be more effective than STM alone.
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Background
Borderline Personality Disorder (BPD) is a severe disor-
der with substantial social cost [1]. Individuals affected
by severe BPD are often heavy users of psychiatric and
medical services [2], entailing high costs for Mental
Health Services (MHS). A previous study conducted by
Ferrero and Coworkers [3] highlighted that, during a
three-year period of data collection in an Italian MHS,
about 10% of patients, which were all heavy users of the
service, used nearly the 50% of the available resources.
About 50% of these heavy users were affected by BPD.
Clinical experience, supported by a recent systematic
review of literature [4], shows that both BPD severity of
symptoms and social impairment are not adequately
improved by medications. Scientific evidence demon-
strates that, to interrupt this pattern of high use, the lack
of effective drug treatments should be balanced by the
addition of psychotherapy within the available treatment
options [2]. Other studies sustain that the management
of heavy MHS users could be improved by training MHS
team about psychological core dimensions of BPD [5].
Currently, both cognitive-behavioral and psychody-
namic psychotherapies for BPD seem effective to reduce
psychopathological severity [6]. It has been also sug-
gested that long-term treatments could be useful to
avoid drop-out in patients with attachment disturbances
[7]. Nevertheless, these approaches are often unavailable
due to the lack of resources and they do not resemble
to treatment as usual [8]. In current practice, MHS
users affected by BPD often do not undergo psychother-
apy and moreover the staff is not specifically trained in
BPD treatment [3].
On the other hand, short-term treatments which are
currently effective for BPD individuals as Dialectical
Behavior Therapy (DBT) [9] are useful to target some
specific disruptive behaviors of severe BPD, but they are
less effective in reducing heavy MHS use, probably
because of affectivity core features, such as intolerance
of aloneness and conflicts on dependence [10].
Another issue, related to the affective core of BPD is
the tendency to “pushing the limits” in building thera-
peutic alliance. This is not necessarily related to self-
damaging or disrupting behaviors but it may produce a
high rate of MHS use and difficulties in clinical manage-
ment [11]. New kinds of treatment, focused on the
affective “core” of BPD patients, are thus needed to
reduce MHS overuse.
Short-term treatments, less complex than long-term
psychodynamic psychotherapies but more tailored to the
extensive problems of BPD individuals, need to be
developed in order to reduce their heavy MHS use [6,8].
Furthermore, MHS team need to receive specific train-
ing, supervision and support in these models of psy-
chotherapy [5] to promote a clinical coherent view [12].
As highlighted by Kerr [5], the effects of these thera-
peutic approaches on severe BPD population still
received limited investigations. Moreover, since the
adjunct of a time-limited psychodynamic psychotherapy
to Supervised Team Management (STD), is more com-
plex than the addiction of a specific training alone to
MHS staff, it is necessary to prove that time-limited psy-
chodynamic psychotherapy is really cost-effective for
BPD patients’ outcome.
The aim of this study was to compare the effectiveness
of STM comprehending specific staff training and super-
vision to the same treatment with the addition of a
time-limited weekly psychodynamic psychotherapy
(Sequential Brief Adlerian Psychodynamic Psychother-
apy, SB-APP) on randomized BPD patients who meet
the criteria for heavy and long-term users of MHS refer-
ring to a specific mental health outpatient service.
Moreover, we aimed to show that SB-APP is useful to
achieve a better outcome in general functioning of BPD
patients, who are high and long-term users of MHS,
with respect to STM. In order to identify some peculiar
therapeutic elements [13], we hypothesized that these
two interventions could be addressed to different core
psychopathological features of BPD [14,15]: supportive
as usual interventions are focused on individuals’
impairment while SB-APP is carefully focused on per-
sonality functioning.
Methods
Patients
We started recruiting on January 1st, 2004, until January
1st, 2008. We enrolled 81 users of the outpatient service
of the Mental Health Center of Chivasso (Turin), Italy,
who had been treated and clinically managed at least
one year. Inclusion criteria were: (a) diagnosis of BPD
according to DSM-IV-TR criteria; (b) age ranging
between 20 and 50 years; (c) heavy use of MHS
throughout the prior year; (d) absence of an acute
comorbid Axis I disorder requiring hospitalization; (e)
no current Substance Dependence Disorder; (f) no Men-
tal Retardation; (g) no previous psychotherapy interven-
tions; and (h) valid informed consent. Diagnostic
assessments for Axes I and II disorders were conducted
at baseline by two trained psychiatrists, using the Struc-
tured Clinical Interview for DSM-IV [16,17].
Heavy and long-term use was defined as follows,
according to previous literature [3]: a) more than six
interventions in emergency departments in the prior
year; b) more than 52 outpatient visits in the prior year,
and c) more than 12 unscheduled outpatient interven-
tions by psychiatrists in the prior year. Patient could be
recruited in the study if at least only one criteria was met.
Figure 1 shows the flowchart of recruitment. Among
the whole sample of BPD patients, 23 did not meet
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criteria for heavy and long-term use of MHS. Eighteen
BPD patients with heavy users features were also
excluded due to several factors: age (n = 2); acute Axis I
disorder requiring hospitalization (n = 8); comorbid
Mental Retardation (n = 2) or Substance Dependence
Disorder (n = 6). Five patients who met the inclusion
criteria refused to participate in the study or to provide
a valid informed consent and five patients refused to fill
in the self-administered questionnaires. Therefore, the
final sample consisted of 35 heavy users of MHS with a
diagnosis of BPD.
Procedures
All procedures were approved by the Institutional Ethic
Committee of Chivasso Mental Health District and were
conduced according to the 1995 Declaration of Helsinki
as revised in Edinburgh in 2000.
Patients, after providing their informed consent, were
randomly assigned to SB-APP in addition to Supervised
Team Management (STM; n = 18) or to STM alone (n
= 17) groups. The random allocation was generated
using a random number table and was carried out by
one author (BR), who was not involved in patients’ clini-
cal management. Patients were enrolled by a psychiatrist
of the MHS who communicated the generalities of the
participants who signed the informed consent to BR and
received from BR the group assignment. The treatment
allocation was assured by both psychiatrist and psy-
chotherapist. Then the psychiatrist explained to partici-
pants that all treatments considered in this study were
supposed to be effective. The team was informed by the
psychiatrist of patients’ allocation to each branch of the
study; each participant was assigned to a psychotherapist
who knew what treatment the patient was undergoing.
The psychotherapist structured the sessions with the
patient accordingly to treatment assignment.
Treatments of each branch were conduced simulta-
neously and both started the week after the enrollment
in the study.
To measure treatment efficacy four assessments were
set for both self-administered and hetero-administered
scales: at intake (T0), after three (T3), six (T6), and 12
months (T12). Two further time points at 18 months
(T18) and 24 months (T24) from enrollment were set
for hetero-evaluation only.
STM group received the usual treatment for 12
months. STM treatment also included sessions of psy-
chological support focused on patients’ social impair-
ment, which were not structured in a time-limited
psychotherapy treatment. SB-APP group received the
usual treatment plus SB-APP (40 weekly sessions) for 10
or 11 months. At the end of the first year (T12), STM
group continued with the as-usual management with
supportive weekly sessions whilst the SB-APP group was
carried on with psychiatric, nurse and educational man-
agement without any individual psychological support.
The number of sessions performed by the two groups in
the first year (T0-T12) was planned to be comparable,
reducing the bias about the number of session.
All psychotherapists were licensed graduate psycholo-
gists and all of them had a personal analytic training
and a specific training in SB-APP. Psychotherapists were
not electively assigned to one group or another but
could indifferently perform single supportive sessions
with certain patients and a structured cycle of SB-APP
with others. In this way both influence of personal skills
and attitudes of the therapists on the outcome of the
study could be reduced.
Supervised team management (STM)
STM included: (a) medications, (b) unstructured psycho-
logical support focused on socio-relational impairment,
(c) rehabilitative interventions, and (d) MHS training.
Medications were administered according to APA guide-
lines for BPD [18]. Three classes of drugs were used:
antidepressants (selective serotonin reuptake inhibitors
[SSRI] or serotonin-noradrenalin reuptake inhibitors
SNRI/noradrenergic and specific serotonergic antide-
pressants [NaSSA]s), mood stabilizers (valproate, lamo-
trigine), and atypical antipsychotics (olanzapine,
Figure 1 Patients’ selection and dropout. The figure displays the
flow-chart of patients’ selection and dropout during the course of
the recruitment, treatment and follow-up.
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aripiprazole, risperidone, quetiapine). Drug treatment
was prescribed during the first or the second visit and
modified if necessary during follow-up by the clinical
manager. Side effects were monitored when clinically
significant. Psychological support was provided by psy-
chotherapists while rehabilitative interventions by
nurses, educators, or psychologists.
Since the beginning of the study, the multidisciplinary
MHS Team of Chivasso in Italy (psychiatrists, psycholo-
gists, nurses and educators) was trained in BPD treat-
ment [12]. They were involved in: 1) preliminary brief
educational program concerning etiology, symptoms and
care of BPD; 2) regular supervisions, in order to pro-
mote a coherent treatment planning; 3) biweekly case
supervision sessions (lasting 90 minutes), and monthly
case discussions (lasting 60 minutes) to share profes-
sional and emotional loads. The conductor was a psy-
chodynamic-oriented psychiatrist, trained in group
dynamics.
No other changes were made to the as-usual approach
to BPD patients recruited in the study. Thus, the team
was free to manage therapy, sessions and other proce-
dures without any limitation and on the basis of clinical
needs. The only exception was the assignment of ran-
domly selected participants to a cycle of psychotherapy
(SB-APP).
Sequential Brief-Adlerian Psychodynamic Psychotherapy
(SB-APP)
SB-APP, derived from Brief-Adlerian Psychodynamic
Psychotherapy (B-APP) [19,20], is a time-limited (40
weekly sessions) psychodynamic psychotherapy based on
Alfred Adler’s theory and delivered in sequential and
repeatable modules [20].
SB-APP is focused specifically on four Personality
Functioning Levels (PFL). These are assessed by the
therapists on the basis of symptoms, quality of interper-
sonal relationships, overall social behaviors, cognitive
and emotional patterns, and defense mechanisms [21].
At PFL 1, SB-APP is focused on preventing disruptive
acting-out by providing reality testing by strengthening
self-reflective functions and identity. At PFL 2, the
approach is focused on increasing empathy through vali-
dating thoughts and emotions and decreasing the sense
of emptiness, egocentrism, and dependence. At PFL 3,
therapy aims at reducing idealization and increasing
continuity and adaptation. At PFL 4, it attempts to
develop increased tolerance for ambivalence, help
patients overcome conflicts, enhance autonomy, and
increase positive attitudes toward the project [20].
SB-APP is devoted to building a favorable working alli-
ance. Practitioners conceptualize interventions along a
continuum and do not make a sharp distinction between
encouraging the patient to search for solutions and
providing them (Encouraging Position Axis, EP-AX) or
between explorative (i.e., interpretation and confronta-
tion) or validating (i.e., empathic validation) techniques
(Technical Instruments Axis, TI-AX). Analogously, psy-
chological functioning is placed along a continuum for
the purpose of treatment planning. Intensive psy-
chotherapies are mainly characterized by the elaboration
of personal experiences by the patient; while supportive
ones are mainly characterized by the integration of the
therapist’s contributions (Intensive Supportive Axis, IS-
AX). Nevertheless, the therapist selects each “technical
instrument” to serve either a conservative (respecting and
strengthening the patient’s defensive structure) or muta-
tive (provoking a change in the patient’s defense mechan-
isms) purpose (Mutative Conservative Axis, MC-AX) on
the basis of the patient’s personality organization [20,22].
In order to preserve compliance to treatment, all psy-
chotherapists underwent biweekly supervisions in addi-
tion to monthly case discussions. The supervisor (AF,
one of the theorists and teaching psychotherapists of
SB-APP) ascertained that all therapists could properly
identify and distinguish PLF 1, 2, 3, 4 accordingly to
their aforementioned definition. Moreover, he moni-
tored their adherence to SB-APP technique and its
application accordingly to participants’ PLF.
Measures
Participants were asked to complete several question-
naires and rating scales were administered by two inde-
pendent raters at each follow-up: at T0 it was only
administered a dimensional personality inventory (Tem-
perament and Character Inventory - TCI); at T0, T3,
T6, T12 some self-rated psychopathological measures
(Symptom Checklist-90 - SCL-90; State-Trait Anger
Expression Inventory - STAXI); at T0, T3, T6, T12,
T18, T24 hetero-administered rating scales (Clinical
Global Impression - CGI, Global Assessment of Func-
tioning - GAF, Clinical Global Impression Modified -
CGI-M).
The Working Alliance Inventory-Short Form (WAI-S)
was filled in by participants only at T12, to evaluate the
different degree of therapeutic alliance between SB-APP
and STM groups after treatment. The raters were
trained in the use of this rating scale, to ensure good
internal consistency and inter-rater reliability, and they
were blind with regard to the group assignment of
patients.
Global Assessment of Functioning (GAF) evaluates the
level of social and occupational functioning of the
individual.
Clinical Global Impression (CGI) is a one-item assess-
ment tool administered by clinicians to evaluate severity
of illness with a score ranging from 0 (non-assessed) to
7 (extreme severity).
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Clinical Global Impression-Modified (CGI-M) uses the
same scoring system of the CGI to assess the severity of
each of nine items included in the DSM-IV diagnostic
criteria for BPD [23]: 1) fear of abandonment; 2) dis-
turbed relationships; 3) identity distortion; 4) impulsiv-
ity; 5) suicidality and self-damaging acts; 6) affective
instability; 7) chronic feelings of emptiness; 8) anger
reactions; and 9) dissociative symptoms.
Symptom Checklist-90 Revised (SCL-90-R) [24] is a
self-report tool, used to identify psychopathological dis-
tress, consisting of nine psychopathological dimensions:
I. Somatization; II. Obsessive-Compulsiveness; III. Inter-
personal Sensitivity; IV. Depression; V. Anxiety; VI.
Hostility; VII. Phobic Anxiety; VIII. Paranoid Ideation;
and IX. Psychoticism. In consideration of the high num-
ber of scales of this study and of the heterogeneity of
BPD symptomatology, only SCL-90-R total score, with-
out subscales, was considered as reliable outcome mea-
sure. It has been used as raw score in statistical analyses.
State-Trait Anger Expression Inventory (STAXI) [25] is
a 44-item self-report questionnaire that measures the
experience and expression of anger. It consists of 44
items divided into six scales and two subscales. The
Trait-Anger (T-ANG) scale includes two subscales: T-
Anger/T, which measures angry temperament, and T-
Anger/R, which measures reaction to criticism. The
Anger Expression-In (AX-IN) scale measures anger sup-
pression, the Anger Expression-Out (AX-OUT) scale
measures the anger expression toward other people or
objects, and the Anger Expression-Control (AX-CON)
scale measures the frequency of attempts to control
anger. Finally, the AX/EX scale provides a general index
of the expression of anger.
The Working Alliance Inventory-Short Form, client ver-
sion (WAI-S) measures the working alliance in therapeu-
tic settings [26]. The WAI-S is a 12-item self-report
questionnaire consisting of three subscales: 1) how clo-
sely the client and therapist agree about and are
mutually engaged in pursuit of the goals of treatment;
2) how closely the client and therapist agree about how
to reach the treatments goals; and 3) the degree of
mutual trust, acceptance, and confidence between the
client and therapist. The composite score is used as a
global measurement of the working alliance. Respon-
dents are asked to rate each statement on a 7-point
Likert scale ranging from 1 (never) to 7 (always). The
total score ranges from 12 to 84, with higher scores
indicating a stronger working alliance.
Among clinical data, time from the first contact and
number of hospitalization days during the year before
recruitment (Table 1) were compared at T0 to ascertain
the comparability of these two randomized samples.
Days of hospitalization and self-harming episodes were
registered at T0 (Table 1), T12 and T24, referring to the
prior year.
The first criterion of MHS high use was considered as
main clinical outcome: i.e. requiring more than six
emergency interventions in the prior year.
Statistical Analyses
All data analyses were performed using the Statistical
Package for the Social Sciences (SPSS, 16.0). Compari-
son between STM and SB-APP groups was performed
at intake (T0) to assess randomization effects using a t-
test for continuous and a chi-square test for categorical
variables (Table 1). The questionnaire (SCL-90-R,
STAXI) and rating scale (CGI, CGI-M items 1-9, GAF)
scores obtained by the 35 patients at all assessments
(T0, T3, T6, and T12) were compared using a general
linear model ANOVA (GLM - ANOVA) for repeated
measures. The effects of time and time*group were also
analyzed (Tables 2 and 3).
Using GLM - ANOVA for repeated measures the rat-
ing scales (CGI, CGI-M items 1-9, GAF) were compared
at the three follow-up observations (T12, T18, and T24).
The effects of time and time*group were also analyzed
(Tables 3 and 4).
The number of days of hospitalization and self-harm-
ing episodes of BPD participants during the prior year
(T0) and at T12 and T24 were compared using the
GLM - ANOVA for repeated measures.
Table 1 T0 Comparison of STM and SB-APP groups.
STM
(n = 17)
SB-APP
(n = 18)
t-test p <
Age 40.1 ± 10.4 39.2 ± 8.6 .26 .797
Education 9.11 ± 1.8 9.38 ± 2.0 -.41 .679
Time from the first
contact
7.3 ± 6.1 7.9 ± 6.3 -.31 .757
Inpatient treatment (days)
*
21.1 ± 58.1 31.2 ± 66.6 -.48 .634
Self harming incidents 2.3 ± 3.1 3.1 ± 2.5 .71 .405
SCL90-R Total 121.9 ±
86.6
160.1 ±
69.2
-1.44 .158
CGI item 1 T0 3.8 ± .8 4.3 ± .9 -1.68 .102
GAF T0 57.2 ± 9.6 60.2 ± 9.1 -.94 .352
AX-EX T0 31.4 ± 13.2 33.0 ± 11.8 -.37 .710
STM SB-APP chi-
square
p <
Females 9 (53%) 8 (44%) .253 .615
Males 8 (47%) 10 (56%)
*in the year before recruitment in the study
SCL-90-R Tot = Symptom Checklist 90 - Revised, Total score; CGI Item 1 =
Clinical Global Impression; GAF = Global Assessment of Functioning; AX-EX =
anger expression (STAXI). STM = Supervised Team Management group; SB-
APP = Sequential Brief Adlerian Psychodynamic Psychotherapy group
df = 1
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Chi-square test for categorical variables was used to
compare the frequency of high use of MSH in the gen-
eral sample and in the two subgroups relating it to the
GAF scores at T24. The proportion of participants
requiring more than six emergency interventions in
each treatment group was also compared at each time
point and with respect to each group (Table 5).
Finally, GLM - ANOVA was used to compare the
total scores for working alliance (WAI-S) and the num-
ber of sessions performed at T12 (non-structured or
structured with the SB-APP) in STM and SB-APP
groups, controlling for sex, time since first contact with
the MHC, and education (Table 6).
All post-hoc comparisons were made with Bonferroni’s
test (corrected for number of comparisons). Due to the
explorative nature of the study we considered significant an
alpha level of .05 (two-tailed). According to an intention-to-
treat analysis, only those individuals lost to follow-up were
not included in data analysis (one patient in each group).
Results
Sample Description
Seventeen individuals (48.6%) were female, and 18
(51.4%) were male. Their mean age was 39.5 (SD = 9.4;
range 24-57), mean CGI was 4.1 (SD = .9; range 2-6),
and mean GAF was 58.7 (SD = 9.3; range 30-75). Only
13 participants (37.1%) did not show a comorbid Axis I
diagnosis (DSM-IV-TR).
Dropout rate
Few participants dropped out during this study: one
member of the STM branch left between T3 and T6 (no
more contact with the MHS), and another one left the
SB-APP group between T3 and T6 (this patient main-
tained contact with the MHS). The first patient was in
contrast with staff members on an impulsivity base, and
the second dropped out because of the initial requests
of changes during SB-APP.
Two patients of STM group refused to complete the
questionnaires between T6 and T12, and one in SB-APP
group refused to complete the questionnaires between
T6 and T12 but they were included in the statistical
analysis using hetero-administered measures.
Comparison at T0 between the two treatment groups
The two treatment groups did not differ significantly after
randomization (Table 1). The distribution of Axis I disor-
ders in the two groups did not significantly differ (chi-
Table 2 T0, T6, T12, T24 comparisons during the first year of the study: self-administered questionnaires.
VARIABLE Times of observation GLM* p < GLM** p <
T0
(17 vs 18)
T3
(17 vs 18)
T6
(16 vs 17)
T12
(16 vs 17)
SCL-90-R tot
STM 130.9 ± 85.2 102.1 ± 71.7 93.3 ± 62.5 93.5 ± 67.2 7.78 .000° .55 .645
SB-APP 156.6 ± 70.0 137.9 ± 74.4 115.6 ± 72.0 103.1 ± 83.4
S-ANG
STM 17.1 ± 9.0 15.6 ± 7.2 14.2 ± 6.8 13.8 ± 6.5 .40 .747 .87 .458
SB-APP 17.1 ± 8.3 17.7 ± 7.4 16.6 ± 10.4 19.0 ± 12.5
T-ANG
STM 19.9 ± 6.8 19.0 ± 7.3 17.4 ± 7.7 18.8 ± 6.3 .33 .569 .14 .709
SB-APP 22.5 ± 7.9 22.5 ± 6.8 21.9 ± 8.8 22.4 ± 8.8
AX-IN
STM 19.5 ± 4.4 18.8 ± 6.4 18.6 ± 5.0 18.7 ± 5.6 1.24 .298 .35 .785
SB-APP 20.5 ± 4.2 20.2 ± 5.5 18.7 ± 2.9 18.8 ± 3.1
AX-OUT
STM 16.0 ± 6.2 16.9 ± 5.3 15.7 ± 4.3 15.3 ± 4.4 1.19 .317 .33 .803
SB-APP 17.0 ± 4.9 16.4 ± 2.9 16.1 ± 3.7 15.4 ± 4.5
AX-CON
STM 20.9 ± 5.9 19.7 ± 5.5 22.2 ± 6.6 23.8 ± 6.6 6.44 .001° 1.33 .269
SB-APP 19.5 ± 6.0 22.4 ± 3.6 23.4 ± 5.8 25.1 ± 4.2
AX-EX
STM 29.3 ± 13.2 31.9 ± 14.1 28.8 ± 12.7 31.3 ± 9.5 1.01 .391 1.41 .245
SB-APP 33.8 ± 10.7 32.3 ± 9.1 29.8 ± 11.1 27.9 ± 10.4
SCL-90-R Tot = Symptom Checklist 90 - Revised, Total score; S-ANG = state-anger; T-ANG = trait anger; AX-IN = anger expressed inwards; AX-OUT = anger
expressed outwards; AX-CON = anger control; AX-EX = anger expression; * = changes within individuals; ** = differences between treatment groups. ° post-hoc:
SCL-90-R Tot = T6, T12 < T0; AX-CON = T6 > T0.
STM = Supervised Team Management group; SB-APP = Sequential Brief Adlerian Psychodynamic Psychotherapy group
df = 3
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square: 2.402, p < .791): Eating Disorder Not Otherwise
Specified (1 patient in STM group vs 1 in he SB-APP
group), General Anxiety Disorder (2 vs 2), Unipolar Mood
Disorder (3 vs 2), Dysthymia (4 vs 6), Obsessive-Compul-
sive Disorder (0 vs 1), and no Axis I disorder (7 vs 6).
Comparison of scores at T0, T3, T6, and T12
Tables 2 and 3 show the scores of self-administered
questionnaires (SCL-90-R Total score, STAXI) and clini-
cal rating scales (CGI, GAF, and CGI-M 9 items) at
intake (T0), after three (T3), six (T6), and 12 months
(T12). Independently of treatment group, patients were
found to overall improve in terms of general symptoms
and clinical severity (SCL-90-R; CGI; CGI-M 9 items),
global functioning (GAF), and control of anger expres-
sion (STAXI) at T6 and T12. SB-APP treatment seemed
more effective than STM on four CGI-M items at T6
and T12 (Table 3): disturbed relationships (p < .040),
impulsivity (p < .025), self-damaging behaviors (p <
.019), and chronic feelings of emptiness (p < .009).
Comparison of scores at T12, T18, and T24
Table 4 shows the scores of clinical rating scales (CGI,
GAF, CGI-M 9 items) at 12 (T12), 18 (T18), and 24
Table 3 T0, T6, T12, T24 comparisons during the first year of the study: rating scales.
VARIABLE Times of observation GLM* p < GLM** p <
T0
(17 vs 18)
T3
(17 vs 18)
T6
(16 vs 17)
T12
(16 vs 17)
CGI Item 1
STM 3.8 ± .8 3.2 ± .8 3.3 ± .7 3.3 ± 1.0 8.47 .000° 1.33 .258
SB-APP 4.3 ± 1.0 3.7 ± 1.1 3.6 ± 1.1 3.3 ± 1.1
GAF
STM 57.4 ± 9.9 64.1 ± 7.8 65.9 ± 11.6 65.9 ± 11.2 11.61 .000° 2.31 .081
SB-APP 60.2 ± 9.1 62.5 ± 12.2 62.3 ± 12.4 66.4 ± 13.0
CGI-M 1
STM 3.4 ± 1.4 3.1 ± 1.3 2.9 ± 1.3 2.4 ± 1.1 23.27 .000° 2.55 .060
SB-APP 4.2 ± 1.2 3.5 ± 1.6 2.8 ± 1.2 2.6 ± 1.1
CGI-M 2
STM 3.1 ± 1.4 3.0 ± 1.5 2.9 ± 1.2 2.4 ± 1.1 17.68 .000° 2.88 .040°°
SB-APP 4.3 ± 1.5 3.8 ± 1.3 3.2 ± 1.2 2.8 ± 1.3
CGI-M 3
STM 3.2 ± 1.5 2.7 ± 1.1 2.4 ± 1.1 2.2 ± .1 19.69 .000° .24 .869
SB-APP 4.4 ± 1.0 3.9 ± 1.1 3.3 ± 1.0 3.2 ± 1.2
CGI-M 4
STM 2.6 ± 1.3 2.5 ± .7 2.2 ± 1.0 1.8 ± 1.1 18.14 .000° 3.24 .025°°
SB-APP 3.5 ± 1.4 2.6 ± 1.3 2.4 ± 1.1 2.0 ± 1.0
CGI-M 5
STM 2.1 ± 1.5 1.7 ± 1.0 1.6 ± .7 1.4 ± .7 25.03 .000° 6.09 .019°°
SB-APP 3.5 ± 1.9 2.9 ± 1.9 1.8 ± .8 1.5 ± .8
CGI-M 6
STM 2.8 ± 1.3 2.7 ± 1.0 2.4 ± .9 2.2 ± .9 9.61 .000° 1.42 .241
SB-APP 4.3 ± 1.4 3.8 ± 1.5 3.3 ± 1.4 2.9 ± 1.4
CGI-M 7
STM 3.2 ± 1.3 2.9 ± 1.3 2.8 ± 1.2 2.6 ± 1.1 19.23 .000° 2.50 .009°°
SB-APP 4.2 ± 1.2 3.7 ± 1.4 3.4 ± 1.2 2.8 ± .8
CGI-M 8
STM 3.4 ± 1.2 3.3 ± 1.3 2.9 ± 1.1 2.6 ± 1.1 12.32 .000° .64 .592
SB-APP 3.6 ± 1.5 3.1 ± 1.3 2.9 ± 1.2 2.6 ± 1.4
CGI-M 9
STM 2.4 ± 1.1 2.2 ± 1.1 1.6 ± .9 1.6 ± .9 10.77 .000° 1.87 -139
SB-APP 2.9 ± 1.9 2.7 ± 1.8 2.7 ± 1.8 2.3 ± 1.5
STM = Supervised Team Management group; SB-APP = Sequential Brief Adlerian Psychodynamic Psychotherapy group; CGI Item 1: Clinical Global Impression;
CGI-M: CGI modified for BPD subjects. Items: 1) fear of abandonment; 2) disturbed relationships; 3) identity distortion; 4) impulsivity; 5) suicidality; 6) affective
instability; 7) chronic feelings of emptiness; 8) anger reactions; 9) dissociative symptoms. * = changes within individuals; ** = differences between treatment
groups; post-hoc ° = T12 < T6 < T3, T1; °° = SB-APP group showed a greater tendency toward improvement. df = 3
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months (T24). Not significant changes emerged in both
treatment groups during the year after conclusion of
psychotherapy.
Clinical status before and after STM and SB-APP
treatment
Using a GLM for repeated measures, the number of
days of hospitalization and self-harming episodes during
the prior year (T0) was compared with the number of
days of hospitalization and self-harming episodes during
the year of treatment (T12) and after conclusion of
STM or SB-APP intervention (T24).
No significant difference was found between T0 and
T12 in each measure.
We found a significant reduction in the number of
days of hospitalization during the year after conclusion
of treatment (T24; STM: 4.8 ± 9.8; SB-APP: 8.2 ± 19.1)
compared with the year before the study (T0; STM: 21.1
± 58.1; SB-APP: 31.2 ± 66.5), independently of the deliv-
ered treatment (F for time = 4.937; p < .033; F for
time*group = .142; p < .709).
An overall reduction of self-harming episodes was
recorded for both groups during the year before the
time-limited psychological treatments (T0; STM: 2.3 ±
Table 4 T0, T6, T12, T24 comparisons during the second year of the study: rating scales.
VARIABLE Times of observation GLM* p < GLM** p <
T12
(16 vs 17)
T18
(16 vs 17)
T24
(16 vs 17)
CGI Item 1
STM 3.3 ± 1.0 3.2 ± .9 3.1 ± 1.0 .36 .696 1.79 .174
SB-APP 3.3 ± 1.1 3.4 ± 1.0 3.4 ± .9
GAF
STM 65.9 ± 11.2 64.7 ± 14.0 65.6 ± 13.4 .53 .589 .01 .987
SB-APP 66.4 ± 13.0 65.6 ± 13.0 66.2 ± 11.9
CGI-M 1
STM 2.4 ± 1.1 2.4 ± 1.1 2.3 ± 1.0 .19 .827 .41 .661
SB-APP 2.6 ± 1.1 2.6 ± 1.0 2.7 ± 1.0
CGI-M 2
STM 2.4 ± 1.1 2.1 ± 1.1 2.2 ± 1.1 1.46 .238 .24 .784
SB-APP 2.8 ± 1.3 2.7 ± 1.2 2.8 ± 1.2
CGI-M 3
STM 2.2 ± 1.0 2.2 ± 1.1 2.0 ± 1.2 .16 .855 1.02 .365
SB-APP 3.2 ± 1.2 3.3 ± 1.2 3.4 ± 1.3
CGI-M 4
STM 1.7 ± 1.1 1.9 ± 1.0 2.3 ± .5 1.85 .166 2.17 .122
SB-APP 2.1 ± .9 2.2 ± .7 2.1 ± .6
CGI-M 5
STM 1.4 ± .7 1.5 ± .8 1.4 ± .6 .58 .563 .30 .739
SB-APP 1.8 ± 1.0 1.7 ± .9 1.7 ± .9
CGI-M 6
STM 2.3 ± .9 2.0 ± 1.0 2.1 ± 1.1 1.03 .362 .04 .958
SB-APP 2.9 ± 1.4 2.7 ± 1.3 2.8 ± 1.5
CGI-M 7
STM 2.6 ± 1.1 2.4 ± 1.1 2.2 ± 1.1 2.31 .108 1.32 .274
SB-APP 2.8 ± .8 2.9 ± .8 2.8 ± .9
CGI-M 8
STM 2.6 ± 1.1 2.5 ± 1.2 2.4 ± 1.3 1.06 .350 .02 .972
SB-APP 2.6 ± 1.4 2.5 ± 1.3 2.4 ± 1.3
CGI-M 9
STM 1.6 ± .9 1.8 ± 1.1 1.4 ± 1.0 1.41 .250 .07 .927
SB-APP 2.3 ± 1.5 2.3 ± 1.7 2.1 ± 1.3
STM = Supervised Team Management group; SB-APP = Sequential Brief Adlerian Psychodynamic Psychotherapy group; CGI Item 1: Clinical Global Impression;
CGI-M: CGI modified for BPD subjects. Items: 1) fear of abandonment; 2) disturbed relationships; 3) identity distortion; 4) impulsivity; 5) suicidality; 6) affective
instability; 7) chronic feelings of emptiness; 8) anger reactions; 9) dissociative symptoms. * = changes within individuals; ** = differences between treatment
groups. df = 2
Amianto et al. BMC Psychiatry 2011, 11:181
http://www.biomedcentral.com/1471-244X/11/181
Page 8 of 14
3.1; SB-APP: 3.1 ± 2.5) and the year following their con-
clusion (T24; STM: .4 ± .8; SB-APP: .3 ± .6), irrespective
of treatment group (F for time = 33.370; p < .000; F for
time*group = 1.357; p < .252).
Heavy users and Global Functioning during the Follow-up
year
The number of performed sessions at T12 was planned
to be the same (40 vs 40 weekly sessions). Supportive
setting was maintained until T24 and so it did not sig-
nificantly differ between STM (n = 85.4 ± 12.2) and SB-
APP (n = 80.7 ± 6.3) groups (t = 1.403; p < .171).
Only 23.5% (n = 8/34) of the sample met the criteria for
MHS heavy use at T24 (chi-square = 38.919; p < .001).
The proportion of individuals in the two groups
requiring more than six emergency interventions, first
criterion for heavy use of MHS, did not differ at T24 (n
= 5/16 in the STM group and n = 3/18 in the SB-APP
group; chi-square = .443; p < .311).
The proportion of patients in the two groups with
GAF scores of at least 60 at T24 did not differ (n = 10/
16 in the STM group, n = 14/18 in the SB-APP group;
chi-square = .457; p < .275).
Patients with lower GAF scores at T24 were also more
likely to remain heavy users at this time (n = 5/8 heavy
users had GAF < 60 at T24; F = 5.517; p < .031). Thus,
individuals without sufficient improvement in symptoms
and social functioning after two years of treatment
remained heavy users of MHS.
Working Alliance
The WAI-S total score at T12 using GLM ANOVA
(Table 5) was found to be related to two indepen-
dent factors: time from the first contact with MHS
(TIME; r = -.329; p < .048) and treatment group
(SB-APP vs. STM) with total scores on working alli-
ance higher in SB-APP group at post-hoc analysis
(STM: 46.7 ± 8.8 and SB-APP: 53.2 ± 6.3; t = -2.426;
p < .021; Table 5).
Discussion
Three main results emerged from this study: 1) the
branch of the study including specific MHS team super-
vision in addition to treatment-as-usual (STM) showed
an improvement in the symptoms and functioning com-
pared to baseline, even though a structured psychother-
apy was not applied; 2) the improvement was found to
be stable over time; 3) a time-limited psychodynamic
psychotherapy focused on patients’ level of personality
functioning (SB-APP) was more effective than STM
with respect to some core psychopathological character-
istics of BPD (disturbed relationships, impulsivity, sui-
cidality/self-damaging behaviors, and chronic feelings of
emptiness) and working alliance.
Table 5 T0, T12, T24 comparisons during the second year of the study: clinical outcomes.
VARIABLE Times of observation GLM* p < GLM** p <
T0
(17 vs 18)
T12
(16 vs 17)
T24
(16 vs 17)
Inpatient treatment (days)
STM 21.1 ± 58.1 17.3 ± 53.2 4.8 ± 9.8 4.937 .033 .142 .709
SB-APP 31.2 ± 66.6 26.5 ± 54.7 8.2 ± 19.1
Self harming incidents
STM 2.3 ± 3.1 2.2 ± 2.8 .4 ±.8 33.370 .000 1.337 .252
SB-APP 3.1 ± 2.5 1.9 ± 2.0 .3 ±.6
chi-square* p < chi-square** p <
> 6
Emergency Interventions
STM 12/17(70%) 7/16(40%) 5/16(30%) 5.591 .061 9.764 .135
SB-APP 10/18(61%) 6/17(33%) 3/17(18%) 5.472 .065
STM = Supervised Team Management group; SB-APP = Sequential Brief Adlerian Psychodynamic Psychotherapy group; * = changes within individuals; ** =
differences between treatment groups.
df = 2 for GLM and for chi-square*; df = 6 for chi-square**
Table 6 Working Alliance at T12. General Linear Model:
ANOVA controlling for possible confounding variables.
F Sig.
Intercept 41.31 .000
Education .24 .628
Time from the first contact with MHS 4.83 .037*
Group (STM or SB-APP) 6.99 .013**
Sex .13 .718
Group * Sex .01 .992
STM = Supervised Team Management group; SB-APP = Sequential Brief
Adlerian Psychodynamic Psychotherapy group.
Dependent variable: WAI-S Total Score. * = inverse correlation between WAI-S
score and time since the first contact with MHS; ** = the WAI-S score is
higher in the SB-APP group than in the STM group (see text).
df = 1
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With regard to the first point, both patients and raters
reported that one year of treatment as usual, compre-
hending specific MHS team training and supervision,
improved in both psychopathological expression and
substantial reduction of heavy use of MHS. These data
provide support to design a randomized controlled trial
to demonstrate that the addition of team training may
have a role in obtaining these effect. The whole group
of patients reported a significant improvement in gen-
eral psychopathology and in anger control during treat-
ment and at the first-year follow-up. STM effectiveness
is even more extensively confirmed by hetero-adminis-
tered scales, showing a significant improvement in all
CGI scores.
These results are in line with previous studies and are
interesting because a better management of anger is an
important target when treating BPD patients [27]. This
may be consequent to a greater consistence of MHS
team management and/or to a reduction of counter-
transferal reactions by therapeutic team which could eli-
cit BPD patients’ anger [28]. Indeed, anger reactions are
often explosive and prolonged, constituting indeed
major risks factors for suicidality [29].
An overall improvement in clinical severity (CGI), glo-
bal functioning (GAF), and all nine psychopathological
domains included in the diagnosis of BPD (CGI-M
items 1-9) were reported by blind, trained researchers.
The overall improvement in global functioning (GAF)
after one year is particularly important because person-
ality disturbances lead to social dysfunction to a greater
extent than the majority of other pathologies and
patients quality of life may remain poor even after well-
designed therapeutic interventions (i.e. Cognitive Beha-
vioral Therapy for Personality Disorders - CBT-PD)
[30]. Besides, poor social adjustment is a risk factor for
suicide attempts among patients with BPD [29]. More-
over, individuals who did not reach a sufficient GAF
level remained heavy users of MHS at T24.
The improvement of anger control in our sample
could have a role on reduction in self-damaging beha-
viors and hospitalization rates during the year after psy-
chotherapeutic treatment. Further studies are necessary
to confirm this causal hypothesis.
Finally, the significant improvement of the main out-
come measure of this study, i.e. recurrence of high use
of psychiatric service at the two-year follow-up, showed
that the interventions were effective on this core pro-
blem afflicting both patients and service. These results
are consistent with literature findings. Among medium-
term interventions ranging from 12 to 18 months, one
year of DBT was superior both to treatment-as-usual
(TAU) and treatment by community experts with regard
to self-harm, suicidality, hospitalization and psychiatric
emergency visits reduction [9]. Also eighteen months of
Mentalization Based Treatment (MBT) showed better
results than TAU concerning a steeper decline of both
self-reported and clinically significant problems, includ-
ing suicide attempts and hospitalizations [31]. Similarly,
Transference Focused Psychotherapy (TFP) [32] was
more effective than treatment by experts in reducing
suicidality and in inpatient psychiatric treatment, but
not in self-harming behaviors. Finally, there is evidence
of benefit from adding CBT-PD to TAU on suicidal
attempts, state anxiety and dysfunctional beliefs [33].
Among brief treatments, a shorter form of DBT (DBT-
B; 6 months of duration) lead to significant decreases in
self-injure, suicide ideation and overall patients subjec-
tive distress, but not to a reduction of hospitalizations
and emergency visits [34].
BPD patients are high users of MHS because they
need several repeated treatments, including urgent inter-
ventions either in community settings or in emergency
departments [2,9]. The reduction of dramatic occur-
rences and unscheduled interventions in both groups of
patients underlines that a significant component of bor-
derline malfunction can be reduced correcting therapeu-
tic behaviors that worsen symptoms [28,35] by a specific
MHS team training. Working with a precise theoretical
framework and being supported by a specialist supervi-
sion which addresses relational dynamics of the thera-
peutic team is useful with BPD, a disorder which heavily
challenges consistence and coherence of operators
[5,12]. Data showed in this study strongly encourage
MHS teams to adopt similar supervision procedures.
As regards the second finding of this study, our data
analysis of the scores at the second-year follow-up did
not show any significant change in psychopathology or
clinical scores and no significant differences at the
between-group analysis were found. Nevertheless, the
evaluation of heavy use status underscores that at the
two-year follow-up the majority of BPD patients are no
more heavy MHS users. This sustains a stability of
improvement one year after the beginning of the inter-
vention. This stability has been supported by the persis-
tence of the STM with team supervision in the follow-
up period. Nevertheless, this suggests that: 1. improve-
ment from the initial therapeutic approach (without
team supervision) to the therapeutic approach with
team supervision (STM) leads to an enduring better
functioning of BPD patients; 2. STM with supervision
alone is not able to significantly further improve
patients’ functioning after one year of treatment; 3.
improvement of BPD functioning reached with a better
clinical management is sufficient to significantly reduce
the heavy use of the service at two-year follow-up; 4.
more specific treatments (possibly SB-APP) are needed
to further improve BPD psychopathology beyond the
functioning level obtained in first year of both
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treatments. In fact, the high non-homogeneity of BDP
diagnoses require tailored treatments based on specific
clinical, psychopathological and functioning (PLF) char-
acteristics [13].
These data have to be confirmed by longer follow-up
periods. BPD patients treated with CBT-PD showed a
stable improvement after 6 years [30] and patients trea-
ted with MBT after 8 years [36].
As concerns the third finding of this study, one of the
major aims was to compare two different therapeutic
techniques: STM with and without a structured cycle of
SB-APP. Research supports that BPD treatment may
benefit from a structured approach to psychotherapy
[31], since patients are often chaotic in their lives and
relationships and have a deficient psychic structure [8].
The effectiveness of well structured treatments might
widely relate to common factors such as stable frame-
work, active and empathic therapist, attention to coun-
tertransference and progressive patients’ awareness
connecting feelings, thoughts and behaviours [37-39]
and not to specific techniques [8]. Nevertheless, focusing
on specific psychopathological processes could add ben-
efits to structured clinical support [40].
SB-APP is a time-limited psychopathology-based
intensive-supportive psychotherapy derived from B-APP,
a 15-session time-limited treatment that has been used
with good results [19], either alone or in combination
with medication, for treating outpatients with mood and
anxiety disorders [40] or eating disorders [41], also in
comorbidity with personality disorders. The SB-APP was
conceived because of the BPD individuals relationship
disturbances, fears of abandonment and severe difficul-
ties with building a stable therapeutic alliance [20].
Several treatments [9,30-34,36] are useful to address
specific disruptive behaviors of severe BPD, but are less
effective in reducing heavy MHS use related to intoler-
ance of aloneness and conflicts over dependency [10] or
the tendency of “pushing the limits” in building thera-
peutic alliance which produce a high rate of MHS use
and great problems in BPD management [11].
Since the same therapists of the team performed both
kind of interventions with different patients SB-APP,
superiority to STM was not related to therapists’ subjec-
tive skills but possibly to the specific setting and techni-
que of the structured treatment with respect to the
unstructured psychological support. In order to treat
acting out and impulsivity (CGI-M, item 4) and self-
damaging behaviors (CGI-M, item 5), an accurate iden-
tification of patients’ cognitive and emotional patterns
and defense mechanisms [15] is required: this represents
the SB-APP specific focus. Distorted relationships and
acting out (CGI-M, item 2) could also benefit from a
well structured treatment setting. Moreover, patients
feelings of emptiness (CGI-M, item 7) are very
persistent and have different psychopathological features
during evolution of BPD [21]. Consequently, SB-APP
therapists address patients emptiness with either pro-
moting mentalization [42] (PFL 1) or decreasing split-
ting defenses (PFLs 2 and 3) and increasing tolerance
for ambivalence (PFL 4).
Considering remaining CGI-M items: dysphoria and
anxiety (CGI-M, item 6), rage (CGI-M, item 8), as well
as paranoid ideation (CGI-M, item 9) are likely to be
decreased by pharmacological therapy. Increasing better
skills to cope novelty with risk, as in unstructured psy-
chological support, and providing empathic validation
and encouragement to elaboration, as in SB-APP, are
likewise useful to reduce affective and cognitive symp-
toms. Furthermore, treatment of fear of abandon (CGI-
M, item 1) might benefit from implicit aspects of thera-
peutic relationship
Patients’ identity instability (CGI-M, item 3) may be
reduced by identification with therapists, irrespectively
from their technique [43].
The client-rated quality of therapeutic alliance was
rated only at the end of follow-up because of the diffi-
culties in alliance-building and early termination of
treatment [44]. Structured psychotherapy was more
effective in building a good and stable therapeutic rela-
tionship. In fact, individuals treated with SB-APP
described their therapist as more empathic and confi-
dent and rated a better working alliance than did those
in the STM group.
A detailed cost-effectiveness analysis considering the
savings due to the reduction of high MHS use (repeated
hospitalizations, unscheduled sessions, at home inter-
ventions, loss of working days, etc.) was not performed
in the present study to support the opportunity of SB-
APP. SB-APP costs are represented by specific training
to therapists and by the need of performing 40 struc-
tured weekly sessions with the psychotherapists. In our
study, the total number of T0-T12 sessions was the
same in the two treatment branches. Nevertheless, at
T12 and T24follow-up SB-APP allowed to avoid the
weekly psychological support which was carried on in
the STM group saving about 40 weekly sessions (about
4.000, 00 $/participant).
Conclusions
The hypothesis raised by the present research is that
specific team training supervision and support on BPD
psychopathology improve the outcome of MHS heavy
users with respect to team management. These data
provide support to eminent authors [5,12] claiming that
working with a precise theoretical framework and being
supported by a specialist supervision which addresses
relational dynamics of the therapeutic team is useful
when treating BPD.
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In addition, the present study demonstrates that SB-
APP showed superiority with respect to STM in some
core psychopathological dimensions evaluated with the
CGI-M: disturbed relationships, impulsivity, self-dama-
ging behaviors (including suicidality), and chronic feel-
ings of emptiness.
SB-APP offers an adjunctive outcome in these areas
since it is focused on different core psychopathological
features of BPD [14,15] compared to STM: supportive
interventions are focused on individuals’ impairment,
while SB-APP is mainly focused on personality
functioning.
Moreover, SB-APP has been found significantly more
effective in building the therapeutic alliance.
Not unlike DBT-B and CBT-PD [34,30], SB-APP is a
shorter therapy compared to twelve or eighteen-month
treatments with DBT, TFP and MBT: however, it seems
to be promising in order to treat severe patients with
BPD in a more rapid way and with stable effects.
Finally, also nonspecific agents of structured time-lim-
ited psychotherapy, such as a specific setting and a
more significant therapeutic relationship may be respon-
sible of improved outcome with respect to unstructured
psychological support.
Limitations and perspectives
Concerning SB-APP group, we expected that the higher
improvement in CGI domains and global functioning -
compared with STM - would have produced in this
group a greater reduction or remission of symptoms in
the year after the psychotherapy cycle. On the contrary,
also in SB-APP group a significant improvement was
not found after the first year of follow-up. This may
derive from severe resistance to change which is typical
of personality disorders in general and of BPD patients
in particular. This provides support to subsequent psy-
chotherapy cycles to produce a progression in BDP dis-
order itself which goes beyond the mere overcoming of
heavy MHS use.
Although these results are consistent with those of
other authors [45], we should be cautious about their
relevance due to the complexity of treatments and the
need for further investigation. Larger samples are needed
to confirm these preliminary results in real MHS clinical
practice. Cost-effectiveness analyses are required to con-
firm effectiveness of present results [44,46]. Follow-up
controlled studies are warranted to prove higher benefits
of a structured psychotherapeutic treatment as SB-SAPP
and its cost-effectiveness with respect to STM with
supervision on the long-term period.
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